SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 60
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2025 AND VI 26 AND IP 5
Results: 18
1
2
Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 58
- By:
- Publication type:
- Article
3
First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 55
- By:
- Publication type:
- Article
4
The Long-Term Impact of COVID-19 on Oncology Care: A 5-Year Retrospective.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 48
- By:
- Publication type:
- Article
5
Telehealth Does Not Lead to Unnecessary Care.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 46
- By:
- Publication type:
- Article
6
Researchers Address the Barriers to Remote Breast Cancer Symptom Monitoring in the US.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 45
- By:
- Publication type:
- Article
7
THE MOVE FROM BLOOD TO SOLID: Open Opportunities for CAR T-Cell Therapy in Solid Tumors.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 38
- By:
- Publication type:
- Article
8
Quizartinib Plus Chemotherapy Is Set to Be Evaluated in FLT3-ITD-Negative AML in Phase 3 Trial.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 32
- By:
- Publication type:
- Article
9
Combinations Targeting PI3K/AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 30
- By:
- Publication type:
- Article
10
ctDNA Aids in Elucidating the Role of Select Therapies for CRC.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 26
- By:
- Publication type:
- Article
11
Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 20
- By:
- Publication type:
- Article
12
Tislelizumab Plus Chemotherapy Expands First-Line ESCC Treatment Paradigm.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 14
- By:
- Publication type:
- Article
13
Trastuzumab Deruxtecan Tacks on Indication for Pretreated HER2-Low and -Ultralow Metastatic Breast Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 12
- Publication type:
- Article
14
Brentuximab Vedotin Plus Lenalidomide/Rituximab Receives Green Light for Relapsed/Refractory LBCL.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 12
- Publication type:
- Article
15
Mirdametinib Receives Approval for NF1-Associated Plexiform Neurofibromas.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 12
- Publication type:
- Article
16
Datopotamab Deruxtecan Gets Go-Ahead for Unresectable or Metastatic HR+/HER2-Breast Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 12
- Publication type:
- Article
17
On the Unreality of Cancer Care Finances in the US: An Example of the Emperor's New Clothes Syndrome?
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 10
- By:
- Publication type:
- Article
18
USING TECHNOLOGY to Guide Optimal Treatment.
- Published in:
- OncologyLive, 2025, v. 26, n. 5, p. 8
- By:
- Publication type:
- Article